Genetic Clues to Epilepsy Discovered
|
By LabMedica International staff writers Posted on 29 Aug 2013 |

Image: Positron emission tomography of epileptic brain (Photo courtesy of Seattle Children’s Hospital).
A breakthrough for neurological disorders was reached with innovative genetic technology when two genes were discovered linked to severe forms of childhood epilepsy.
Exome sequencing was used to detect the mutations in DNA sequences that could cause two forms of childhood epilepsy: infantile spasms and Lennox-Gastaut Syndrome—diseases that affect more than two million people in the USA.
A team of scientists led by those at Duke University Medical Center (Durham, NC, USA) screened for de novo mutations in patients with two classical epileptic encephalopathies, 149 who had infantile spasms, and 115 diagnosed with Lennox-Gastaut syndrome. The exome sequences of 264 epileptic children were compared with those of the parents, who did not have the neurological disease. To identify any disease-causing mutations, the investigators analyzed the sequences using various statistical tools.
The results of the study revealed disease-causing mutations in six genes, four of which had been uncovered before in previous studies, but two were discovered for the first time. Among these were the gene encoding for gamma-aminobutyric acid receptor subunit beta-3 (GABRB3), with de novo mutations in four patients, and the gene encoding for the asparagine-linked glycosylation 13 homolog (ALG13), with the same de novo mutation in two patients. Both genes show clear statistical evidence of association with epileptic encephalopathy.
The scientists say that by using novel genetic analysis techniques they also revealed that epilepsy-causing mutations in humans are concentrated in genes that are intolerant or highly sensitive to changes in their DNA sequence. They add that the genes are so sensitive that the smallest change in their DNA sequence means the gene may not work, which could lead to death or severe forms of diseases. Results showed that up to 90 genes could carry epilepsy-causing mutations, and many of these have been previously linked to other neurological disorders, such as autism.
David B. Goldstein, PhD, a study leader, said, “It appears that the time for using this genome approach to understand complex neurological disorders has arrived. One of the most encouraging aspects of this study is that we're beginning to see how best to interpret and make effective use of exome sequence data. We anticipate that further studies will identify many new disease-causing genes and we intend to develop a watch list of the genes which summarizes their clinical characteristics in way that will be helpful for doctors, patients and other scientists." The study was published on August 11, 2013, in the journal Nature.
Related Links:
Duke University Medical Center
Exome sequencing was used to detect the mutations in DNA sequences that could cause two forms of childhood epilepsy: infantile spasms and Lennox-Gastaut Syndrome—diseases that affect more than two million people in the USA.
A team of scientists led by those at Duke University Medical Center (Durham, NC, USA) screened for de novo mutations in patients with two classical epileptic encephalopathies, 149 who had infantile spasms, and 115 diagnosed with Lennox-Gastaut syndrome. The exome sequences of 264 epileptic children were compared with those of the parents, who did not have the neurological disease. To identify any disease-causing mutations, the investigators analyzed the sequences using various statistical tools.
The results of the study revealed disease-causing mutations in six genes, four of which had been uncovered before in previous studies, but two were discovered for the first time. Among these were the gene encoding for gamma-aminobutyric acid receptor subunit beta-3 (GABRB3), with de novo mutations in four patients, and the gene encoding for the asparagine-linked glycosylation 13 homolog (ALG13), with the same de novo mutation in two patients. Both genes show clear statistical evidence of association with epileptic encephalopathy.
The scientists say that by using novel genetic analysis techniques they also revealed that epilepsy-causing mutations in humans are concentrated in genes that are intolerant or highly sensitive to changes in their DNA sequence. They add that the genes are so sensitive that the smallest change in their DNA sequence means the gene may not work, which could lead to death or severe forms of diseases. Results showed that up to 90 genes could carry epilepsy-causing mutations, and many of these have been previously linked to other neurological disorders, such as autism.
David B. Goldstein, PhD, a study leader, said, “It appears that the time for using this genome approach to understand complex neurological disorders has arrived. One of the most encouraging aspects of this study is that we're beginning to see how best to interpret and make effective use of exome sequence data. We anticipate that further studies will identify many new disease-causing genes and we intend to develop a watch list of the genes which summarizes their clinical characteristics in way that will be helpful for doctors, patients and other scientists." The study was published on August 11, 2013, in the journal Nature.
Related Links:
Duke University Medical Center
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







